468.00 +4.80 (1.04%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
458.05
Today’s High
472.95
52 Week Low
387.5
52 Week High
623.51
467.35 +3.40 (0.73%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
459.5
Today’s High
473.7
52 Week Low
390.5
52 Week High
624.11
Key Metrics
- Market Cap (In Cr) 11833.45
- Beta -
- Div. Yield (%) 0.43
- P/B 7.75
- TTM P/E 26.62
- Peg Ratio -10.16
- Sector P/E 27.46
- D/E 0.06
- Open Price 458.05
- Prev Close 463.2
Analysis
Price Analysis
-
1 Week-0.45%
-
3 Months-4.37%
-
6 Month-6.74%
-
YTD-4.22%
-
1 Year-2.92%
Risk Meter
- 32% Low risk
- 32% Moderate risk
- 32% Balanced Risk
- 32% High risk
- 32% Extreme risk
Recos
5 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- Strong Sell
- 0
- Sell
- 0
- Hold
- 0
- Buy
- 2
- Strong Buy
- 3
Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 1320.22
- Selling/ General/ Admin Expenses Total
- 179.96
- Depreciation/ Amortization
- 39.1
- Total Operating Expense
- 779.69
- Operating Income
- 540.53
- Net Income Before Taxes
- 667.59
- Net Income
- 453.8
- Diluted Normalized EPS
- 17.83
- Period
- 2022
- Total Assets
- 1829.59
- Total Liabilities
- 302.41
- Total Equity
- 1527.18
- Tangible Book Valueper Share Common Eq
- 59.9
- Period
- 2022
- Cashfrom Operating Activities
- 330
- Cashfrom Investing Activities
- -136.21
- Cashfrom Financing Activities
- -156.41
- Net Changein Cash
- 37.38
- Period
- 2021
- Total Revenue
- 1009.72
- Selling/ General/ Admin Expenses Total
- 142.84
- Depreciation/ Amortization
- 31.64
- Total Operating Expense
- 600.87
- Operating Income
- 408.84
- Net Income Before Taxes
- 467.67
- Net Income
- 362.34
- Diluted Normalized EPS
- 14.23
- Period
- 2021
- Total Assets
- 1474.47
- Total Liabilities
- 293.66
- Total Equity
- 1180.81
- Tangible Book Valueper Share Common Eq
- 46.28
- Period
- 2021
- Cashfrom Operating Activities
- 382.55
- Cashfrom Investing Activities
- -311.4
- Cashfrom Financing Activities
- -75.66
- Net Changein Cash
- -4.51
- Period
- 2020
- Total Revenue
- 833.79
- Selling/ General/ Admin Expenses Total
- 128.98
- Depreciation/ Amortization
- 23.86
- Other Operating Expenses Total
- 0
- Total Operating Expense
- 472.52
- Operating Income
- 361.27
- Net Income Before Taxes
- 404.51
- Net Income
- 317
- Diluted Normalized EPS
- 12.45
- Period
- 2020
- Total Assets
- 1172.81
- Total Liabilities
- 328.05
- Total Equity
- 844.76
- Tangible Book Valueper Share Common Eq
- 33.07
- Period
- 2020
- Cashfrom Operating Activities
- 415.95
- Cashfrom Investing Activities
- -421.53
- Cashfrom Financing Activities
- 6.37
- Net Changein Cash
- 0.79
- Period
- 2019
- Total Revenue
- 377.83
- Selling/ General/ Admin Expenses Total
- 60.89
- Depreciation/ Amortization
- 11.5
- Total Operating Expense
- 215.09
- Operating Income
- 162.74
- Net Income Before Taxes
- 157.87
- Net Income
- 109.27
- Diluted Normalized EPS
- 4.29
- Period
- 2019
- Total Assets
- 783.02
- Total Liabilities
- 192.73
- Total Equity
- 590.29
- Tangible Book Valueper Share Common Eq
- 23.08
- Period
- 2019
- Cashfrom Operating Activities
- 50.4
- Cashfrom Investing Activities
- -65.48
- Cashfrom Financing Activities
- 25.98
- Net Changein Cash
- 10.9
- Period
- 2022-09-30
- Total Revenue
- 278.4
- Selling/ General/ Admin Expenses Total
- 28.65
- Depreciation/ Amortization
- 12.03
- Other Operating Expenses Total
- 15.68
- Total Operating Expense
- 190.55
- Operating Income
- 87.85
- Net Income Before Taxes
- 98.48
- Net Income
- 72.06
- Diluted Normalized EPS
- 2.83
- Period
- 2022-09-30
- Total Assets
- 1806.02
- Total Liabilities
- 302.96
- Total Equity
- 1503.06
- Tangible Book Valueper Share Common Eq
- 56.6
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 271.4
- Cashfrom Investing Activities
- -41.36
- Cashfrom Financing Activities
- -208.03
- Net Changein Cash
- 22.01
- Period
- 2022-06-30
- Total Revenue
- 338.8
- Selling/ General/ Admin Expenses Total
- 26.59
- Depreciation/ Amortization
- 11.5
- Other Operating Expenses Total
- 19.7
- Total Operating Expense
- 199.42
- Operating Income
- 139.38
- Net Income Before Taxes
- 148.96
- Net Income
- 107.54
- Diluted Normalized EPS
- 4.22
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 363.85
- Selling/ General/ Admin Expenses Total
- 31.12
- Depreciation/ Amortization
- 10.42
- Other Operating Expenses Total
- 18.88
- Total Operating Expense
- 217.25
- Operating Income
- 146.6
- Net Income Before Taxes
- 161.28
- Net Income
- 91.67
- Diluted Normalized EPS
- 3.6
- Period
- 2022-03-31
- Total Assets
- 1829.59
- Total Liabilities
- 302.41
- Total Equity
- 1527.18
- Tangible Book Valueper Share Common Eq
- 59.9
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 330
- Cashfrom Investing Activities
- -136.21
- Cashfrom Financing Activities
- -156.41
- Net Changein Cash
- 37.38
- Period
- 2021-12-31
- Total Revenue
- 391.59
- Selling/ General/ Admin Expenses Total
- 25.01
- Depreciation/ Amortization
- 10.51
- Other Operating Expenses Total
- 12.67
- Total Operating Expense
- 216.07
- Operating Income
- 175.51
- Net Income Before Taxes
- 239.46
- Net Income
- 160.07
- Diluted Normalized EPS
- 6.29
- Period
- 2021-12-31
- Period
- 2021-12-31
- Period
- 2021-09-30
- Total Revenue
- 300.99
- Selling/ General/ Admin Expenses Total
- 23.19
- Depreciation/ Amortization
- 9.18
- Other Operating Expenses Total
- 16.04
- Total Operating Expense
- 188.39
- Operating Income
- 112.6
- Net Income Before Taxes
- 133.93
- Net Income
- 96.98
- Diluted Normalized EPS
- 3.81
- Period
- 2021-09-30
- Total Assets
- 1662.52
- Total Liabilities
- 305.01
- Total Equity
- 1357.51
- Tangible Book Valueper Share Common Eq
- 53.23
- Period
- 2021-09-30
- Cashfrom Operating Activities
- 122.71
- Cashfrom Investing Activities
- -71.39
- Cashfrom Financing Activities
- -41.17
- Net Changein Cash
- 10.16
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day462.2
- 10 Day463.99
- 20 Day455.65
- 50 Day434.24
- 100 Day448.35
- 300 Day486.73
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sanofi India
- 5754.25
- 64.9
- 1.14
- 7778.36
- 5454.1
- 13154.29
- Glenmark Pharmaceuticals
- 434.55
- 4.3
- 1
- 545
- 348.9
- 12152.98
- Suven Pharmaceuticals
- 468
- 4.8
- 1.04
- 623.51
- 387.5
- 11833.45
- Alembic Pharmaceuticals
- 599.7
- 6.05
- 1.02
- 847.95
- 541.1
- 11687.64
- Natco Pharma
- 582.8
- 5.55
- 0.96
- 942.15
- 559
- 10235.98
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sanofi India
- 22.99
- 5.91
- 23.41
- 17.92
- Glenmark Pharmaceuticals
- 10.79
- 1.34
- 14
- 8.4
- Suven Pharmaceuticals
- 26.07
- 7.75
- -
- -
- Alembic Pharmaceuticals
- 22.46
- 2.23
- 20.8
- 15.4
- Natco Pharma
- 76.27
- 2.4
- 13.85
- 23.59
Shareholding
- Category
- Percentage
- No. of shares
- Promoter & Promoter Group Shareholding
- 60%
- 152,740,000
- JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED(InitscapacityassoletrusteeofJastiFamilyTrust)
- 60%
- 152,730,000
- SUDHARANI JASTI
- 0%
- 2,000
- VENKATESWARLU JASTI
- 0%
- 2,000
- SIRISHA JASTI
- 0%
- 2,000
- MADHAVI JASTI
- 0%
- 2,000
- KALYANI JASTI
- 0%
- 2,000
- Public Shareholding
- 40%
- 101,824,956
- Others
- 13.55%
- 34,504,153
- UTI-UNIT LINKED INSURANCE PLAN
- 3.72%
- 9,474,361
- L&T MUTUAL FUND TRUSTEE LIMITED-L&T EMERGING BUSIN
- 1.59%
- 4,047,003
- PGIM INDIA TRUSTEES PRIVATE LIMITED A/C PGIM INDIA
- 1.33%
- 3,397,300
- Others
- 1.63%
- 4,165,868
- Others
- 7.58%
- 19,299,701
- RAMBABU CHIRUMAMILLA
- 2.26%
- 5,743,971
- Others
- 1.24%
- 3,160,022
- TATA AIA LIFE INSURANCE CO LTD-LARGE CAP EQUITY FUND
- 2.15%
- 5,485,090
- Others
- 0.09%
- 216,557
- Others
- 1.89%
- 4,811,419
- Others
- 1.14%
- 2,898,799
- HUF
- 0.53%
- 1,353,687
- Clearing Members
- 0.07%
- 190,205
- Trusts
- 0.02%
- 53,088
- Others
- 0.6%
- 1,518,610
- Others
- 0.35%
- 884,257
- Others
- 0.14%
- 348,638
- Others
- 0.05%
- 119,200
- Others
- 0.05%
- 116,000
- Others
- 0.01%
- 35,000
- Overseas Corporate Bodies
- 0%
- 1,000
- Others
- 0%
- 800
- Others
- 0%
- 227
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 08-Nov-22
- Quarterly Results
- 08-Aug-22
- Quarterly Results
- 09-May-22
- Audited Results & Interim Dividend
- 08-Feb-22
- Quarterly Results & Interim Dividend
- 06-Nov-21
- Quarterly Results
- 13-Aug-21
- Quarterly Results
- 08-Jun-21
- Audited Results & Final Dividend
- 10-Feb-21
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 18-Aug-22
- 09-May-22
- AGM
- 31-Aug-21
- 08-Jun-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 29-Aug-22
- 12-Sept-22
- 09-Sept-22
- 1
- 30-Aug-22
- 12-Sept-22
- 09-Sept-22
- 5
- 02-May-22
- 17-May-22
- 13-May-22
- 1
- 03-May-22
- 17-May-22
- 13-May-22
- 1
- 01-Feb-22
- 16-Feb-22
- 15-Feb-22
- 1
- 02-Feb-22
- 16-Feb-22
- 15-Feb-22
- 2
- 08-Jun-21
- 17-Aug-21
- 13-Aug-21
- 1
- 03-Feb-21
- 18-Feb-21
- 17-Feb-21
- 1
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Suven Pharmaceuticals
- Industry Biotechnology & Drugs
- ISIN INE03QK01018
- BSE Code 543064
- NSE Code SUVENPHAR
Suven Pharmaceuticals Limited is an India-based company that is primarily engaged in providing services to global life science and fine chemical, including custom synthesis, process research and development, scale up and contract manufacturing of intermediates, active pharmaceutical ingredients (APIs) and formulations. The Company operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe and Rest of the World. In India, the Company sells bulk drugs and intermediates, fine chemicals and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In Rest of the World, the Company sells bulk drugs, intermediates and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.
MANAGEMENT
- K. Rao Compliance Officer, Company Secretary
- Venkateswarlu Jasti Managing Director, Executive Director
Company Summary
SUVEN PHARMACEUTICALS SUMMARY
Suven Pharmaceuticals is trading 1.04% upper at Rs 468.00 as compared to its last closing price. Suven Pharmaceuticals has been trading in the price range of 472.95 & 458.05. Suven Pharmaceuticals has given -4.22% in this year & -0.45% in the last 5 days.
Suven Pharmaceuticals has TTM P/E ratio 26.62 as compared to the sector P/E of 27.46. There are 5 analysts who have initiated coverage on Suven Pharmaceuticals. There are 3 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.
The company posted a net profit of 72.06 Crores in its last quarter.
Listed peers of Suven Pharmaceuticals include Sanofi India (1.14%), Glenmark Pharmaceuticals (1%), Suven Pharmaceuticals (1.04%) etc.
FAQs about Suven Pharmaceuticals
Suven Pharmaceuticals is trading at 468.00 as on 2 Dec, 2022 3:40:59 PM. This is 1.04% upper as compared to its previous closing price of 463.2
The market capitalization of Suven Pharmaceuticals is 11833.45 Cr as on 2 Dec, 2022 3:40:59 PM.
The average broker rating on Suven Pharmaceuticals is Strong Buy. The breakup of analyst rating is given below -
- 0 analysts have given a strong sell rating
- 0 analysts have given a sell rating
- 0 analysts have given a hold rating
- 2 analysts have given a buy rating
- 3 analysts have given a strong buy rating
The 52 wk high for Suven Pharmaceuticals is 623.51 whereas the 52 wk low is 387.5
Suven Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 26.62
- Sector P/E: 27.46
- Dividend Yield: 0.43%
- D/E ratio: -
Suven Pharmaceuticals reported a net profit of 453.8 Cr in 2022.
